Advertisement
With these recommendations, all four leading independent proxy advisoryfirms have recommended that Renovis stockholders support the transaction withEvotec.
Advertisement
The Board of Directors of Renovis unanimously recommends that stockholdersvote "FOR" the approval and adoption of the agreement and plan of merger, andthe approval of the merger and related transactions as described in the proxystatement/prospectus.
The company encourages all stockholders to vote their shares promptly byphone, Internet, or by mailing their proxy card, and to contact MacKenziePartners at 800/322-2885 or collect at 212/929-5500 if they have any questionsor need any assistance in voting their shares.
About Renovis
Renovis is a biopharmaceutical company focused on the discovery anddevelopment of drugs for major medical needs in the areas of neurological andinflammatory diseases. The Company's proprietary research programs focus onthe purinergic receptors, P2X3 and P2X7, for the potential treatment of painand inflammatory diseases. In addition, Renovis has a worldwide collaborationand license agreement with Pfizer to research, develop and commercialize smallmolecule vanilloid receptor (VR1).
For additional information about the company, please visithttp://www.renovis.com.
Forward-Looking Statements
This communication contains certain forward-looking statements. Allstatements, other than statements of historical facts, regarding thelikelihood and timing of the completion of the business combinationtransaction involving Evotec and Renovis, the conversion of Renovis sharesinto a right to receive Evotec shares, the anticipated benefits of suchtransaction and the plans and objectives of management are forward-lookingstatements and are based on management's current expectations and estimates.We may not actually achieve these plans, intentions or expectations andRenovis cautions investors not to place undue reliance on our forward-lookingstatements. Actual results or events could differ materially from the plans,intentions and expectations disclosed in the forward-looking statements wemake.
Factors that could cause or contribute to such differences may include,but are not limited to, risks relating to the integration of the technologiesand businesses of Evotec and Renovis, unanticipated expenditures, changingrelationships with customers, suppliers and strategic partners, conditions ofthe economy and other factors described in the Registration Statement on FormF-4 filed with the SEC by Evotec and the most recent reports on Form 10-K,Form 10-Q, Form 8-K and other periodic reports filed by Renovis with the SEC.
Additional information about the transaction
Renovis filed a Current Report on Form 8-K with the Securities andExchange Commission on September 24, 2007, that includes as an exhibit theAgreement and Plan of Merger between Evotec and Renovis. Evotec and Renovishave mailed a joint proxy statement/prospectus to stockholders of Renovis inconnection with the proposed merger. This document contains importantinformation about the merger and should be read before any decision is madewith respect to the merger. Investors and stockholders will be able to obtainfree copies of this document and any other documents filed or furnished byEvotec or Renovis through the w
